The article selected for discussion is : Pronovost P., et al.: An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 355:2725–2732, Dec. 28, 2006. Erratum in: N Engl J Med 356:2660, Jun. 21, 2007."
Please consider the following questions:
1. Many of us are going to be going to institutions with less experienced IRBs and less experience in QI work. What regulatory oversight needs to be in place, if any?
2. Collecting data, especially when the data is not flattering poses some medicolegal risk. Of course, not collecting data does not protect either. How might a QI oversight committee provide some medicolegal protection?
3. What would a robust QI oversight committee look like? What would its function be?
No comments:
Post a Comment